The prospective phase III Dragon IV trial (NCT04208347) has revealed that a multimodal neoadjuvant protocol integrating immune checkpoint inhibitors (anti-PD-1), VEGFR2 inhibitors, and SOX chemotherapy achieved a 3.66-fold increase in pCR rates compared to chemotherapy alone (18.3% vs. 5.0%; p<0.001) in locally resectable G/GEJ adenocarcinoma (25). Here, KDR is linked to gastroesophageal junction adenocarcinoma.